AbbVie Inc. (ABBV) FCF/Share TTM
The fcf/share ttm for AbbVie Inc. (ABBV) is $11.76 with a period-over-period change of +11.57%. Free cash flow per share divides trailing free cash flow by shares outstanding, showing cash generation per share.
ABBV FCF/Share TTM Chart
FCF/Share TTM History
| Date | FCF/Share TTM | % Change |
|---|---|---|
| Q1 2026 | $11.76 | +11.57% |
| Q4 2025 | $10.54 | (9.18%) |
| Q3 2025 | $11.61 | +12.77% |
| Q2 2025 | $10.29 | +18.55% |
| Q1 2025 | $8.68 | (13.67%) |
| Q4 2024 | $10.06 | +14.08% |
| Q3 2024 | $8.82 | (12.18%) |
| Q2 2024 | $10.04 | (18.69%) |
| Q1 2024 | $12.35 | (0.83%) |
| Q4 2023 | $12.45 | (10.84%) |
| Q3 2023 | $13.96 | (0.28%) |
| Q2 2023 | $14.00 | +5.74% |
| Q1 2023 | $13.24 | (2.89%) |
| Q4 2022 | $13.64 | +10.49% |
| Q3 2022 | $12.34 | (1.32%) |
| Q2 2022 | $12.51 | +0.87% |
| Q1 2022 | $12.40 | +0.26% |
| Q4 2021 | $12.37 | +1.39% |
| Q3 2021 | $12.20 | +10.69% |
| Q2 2021 | $11.02 | +9.96% |
| Q1 2021 | $10.02 | +6.31% |
| Q4 2020 | $9.43 | +9.11% |
| Q3 2020 | $8.64 | +0.81% |
| Q2 2020 | $8.57 | (6.15%) |
| Q1 2020 | $9.13 | +6.18% |
| Q4 2019 | $8.60 | (1.35%) |
| Q3 2019 | $8.72 | +1.31% |
| Q2 2019 | $8.61 | (3.12%) |
| Q1 2019 | $8.88 | +2.88% |
| Q4 2018 | $8.63 | +9.71% |
| Q3 2018 | $7.87 | +14.28% |
| Q2 2018 | $6.89 | +10.45% |
| Q1 2018 | $6.23 | +5.90% |
| Q4 2017 | $5.89 | +11.60% |
| Q3 2017 | $5.28 | +26.88% |
| Q2 2017 | $4.16 | +1.56% |
| Q1 2017 | $4.09 | +1.25% |
| Q4 2016 | $4.04 | (4.63%) |
| Q3 2016 | $4.24 | (9.44%) |
| Q2 2016 | $4.68 | +0.49% |
| Q1 2016 | $4.66 | +9.09% |
| Q4 2015 | $4.27 | +59.53% |
| Q3 2015 | $2.68 | +8.41% |
| Q2 2015 | $2.47 | +2.06% |
| Q1 2015 | $2.42 | +31.54% |
| Q4 2014 | $1.84 | (37.82%) |
| Q3 2014 | $2.96 | (1.35%) |
| Q2 2014 | $3.00 | (6.58%) |
| Q1 2014 | $3.21 | (10.65%) |
| Q4 2013 | $3.59 | +4.27% |
| Q3 2013 | $3.44 | (9.58%) |
| Q2 2013 | $3.81 | +7.67% |
| Q1 2013 | $3.54 | (5.53%) |
| Q4 2012 | $3.75 | (3.13%) |
| Q3 2012 | $3.87 | +13.22% |
| Q2 2012 | $3.42 | (9.59%) |
| Q1 2012 | $3.78 | +1.31% |
| Q4 2011 | $3.73 | - |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael